Addendum And I may have a different take than many of the esteemed posters on this site regarding potential SUSTAIN results. I actually believe that the ability to significantly and safely raise HDL and ApoA1 over 24 weeks with a potential decrease in CRP would be a dramatic and profound finding that is novel and important. I think that if RVX can show this, the reaction should be favorable and should generate excitement in the cardiology community, and with appropriate and thoughtful media coverage, should result in upward pressure on stock price. There is no drug out there in our current armamentarium which can do this to any great degree, and most still believe in tried and true Framingham data which suggests that HDL is a negative risk factor for CAD despite the results of the recent and often quoted trial published in Lancet. Statins are great, but there is a lot of room for improvement, and my waiting room is still full of patients with coronary disease despite being on high dose statins.